Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;15(2):147-154.
doi: 10.1007/s11904-018-0388-x.

Quarter Century of Anti-HIV CAR T Cells

Thor A Wagner  1   2
Affiliations
Review

Quarter Century of Anti-HIV CAR T Cells

Thor A Wagner. Curr HIV/AIDS Rep. 2018 Apr.

Abstract

Purpose of review: A therapy that might cure HIV is a very important goal for the 30-40 million people living with HIV. Chimeric antigen receptor T cells have recently had remarkable success against certain leukemias, and there are reasons to believe they could be successful for HIV. This manuscript summarizes the published research on HIV CAR T cells and reviews the current anti-HIV chimeric antigen receptor strategies.

Recent findings: Research on anti-HIV chimeric antigen receptor T cells has been going on for at least the last 25 years. First- and second-generation anti-HIV chimeric antigen receptors have been developed. First-generation anti-HIV chimeric antigen receptors were studied in clinical trials more than 15 years ago, but did not have meaningful clinical efficacy. There are some reasons to be optimistic about second-generation anti-HIV chimeric antigen receptor T cells, but they have not yet been tested in vivo.

Keywords: Chimeric antigen receptor (CAR); HIV; HIV cure; Review; T cell therapy; Therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Thor A. Wagner declares a patent PCT/US2015/024876 pending to Seattle Childrens Hospital.

References

    1. Leibman RS, Riley JL. Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther. 2015;23(7):1149–59. doi: 10.1038/mt.2015.70. - DOI - PMC - PubMed
    1. Tran AC, Zhang D, Byrn R, Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol. 1995;155(2):1000–9. - PubMed
    1. Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014;32(4):1021–31. doi: 10.1002/stem.1611. - DOI - PMC - PubMed
    1. Global report: UNAIDS report on the global AIDS epidemic 2012. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2012
    1. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the GBD 2010. AIDS. 2013 doi: 10.1097/QAD.0b013e328362ba67. - DOI - PMC - PubMed

Publication types

Substances